Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn’s Perianal FistulasMichael De Gregorio, Nik S. Ding, Ashish Srinivasan et al.|Clinical Gastroenterology and Hepatology|2021Cited by 36
Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort studyCraig Haifer, Lena Thin, Ashish Srinivasan et al.|The Medical Journal of Australia|2020Cited by 22
Expert Position Statement: Defining the Role of Intestinal Ultrasound in Assessing Constipation and Faecal LoadingRyan Mathias, Robert V. Bryant, Thomas M Goodsall et al.|Alimentary Pharmacology & Therapeutics|2025Cited by 9
Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort studyCraig Haifer, Lena Thin, Ashish Srinivasan et al.|UWA Profiles and Research Repository (University of Western Australia)|2019Cited by 3
Su437 HIGHER ANTI-TUMOUR NECROSIS FACTOR-ALPHA DRUG LEVELS ARE ASSOCIATED WITH IMPROVED RADIOLOGICAL OUTCOMES IN PATIENTS WITH PERIANAL FISTULISING CROHN'S DISEASE: A MULTICENTRE CROSS-SECTIONAL RETROSPECTIVE STUDYMichael De Gregorio, Nik S. Ding, Tanya Lee et al.|Gastroenterology|2021Cited by 1